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Chart 1. Adjusted absorbance graph 
(Absorbance at 450- Absorbance at 540)- 
(Blank at  450- Blank at 540) 
Chart 2. Relevant ETS-1 Data. 
ABSTRACT 
Arteriovenous (AV) grafts made of 
expanded Teflon are a type of 
vascular access often used in 
hemodialysis.  Stenosis often occurs 
in these grafts as a result of intimal 
hyperplasia at the anastomosis of the 
graft and vein.  One approach to this 
problem is localized drug delivery to 
inhibit intimal hyperplasia, which is 
the focus of our research. The 
literature has shown that intimal 
hyperplasia of an AV graft usually 
happens at the graft-venous 
anastomosis, and also there is 
increased angiogenesis at the site of 
intimal hyperplasia.  In this stage of 
the research project, we tried using 
an ETS-1 inhibitor as a potential drug 
to be delivered with ReGel.  
However, the drug profile has not 
produced the desired results, so in 
the next stage of our research, we 
plan to use an anti-angiogenic 
cancer drug, sunitinib. 
The raw data obtained from this lab was used to 
plot the cumulative release of the ETS-1 
inhibitor.  (Figure 4).  This graph demonstrated 
some concentration dependence on the release.  
In other words, higher concentrations of drug 
were releasing a greater amount of drug into 
their surroundings.  There was a semi-linear 
trend line to the cumulative release, indicating 
that the release was fairly constant and steady.  
The ELISA showed us that the ETS-1 peptide 
was being released in the samples and that 
there was still biotin bound to the peptide.   
 
As a check on our data, we are in the process of 
recording new data from the ETS-1 release and 
re-doing the Excel calculations (Charts 1 and 2).  
Our preliminary checks showed that a mistake 
had been made in copying down a value, so a 
concentration of 546 ng/mL rather than 500 
ng/mL had been mistakenly recorded (Chart 2).  
We are still in the process of checking our 








In examining the graphs that were calculated 
based on the raw data from ELISA (Figure 
4), we found a continuous sustained release. 
However, we also observed that the highest 
concentration of drug (250 µg/mL) initially 
released slightly more drug over time, but at 
around the 6-day mark, the middle 
concentration (66.6 unit) actually started 
releasing more of the ETS-1 inhibitor. Our 
plan is to repeat the experiments and 
analysis to check our accuracy. 
 
Although we plan on continuing to study 
ETS-1, as it has a unique mode of action, we 
are also planning on running a parallel study 
with sunitinib.  Sunitinib is a cancer drug that 
inhibits the growth of capillaries.  Because 
cells generally need to be within 100 µm of a 
capillary in order to survive, sunitinib’s anti-
angiogenic activity may work on the 
hyperplasia at the anastomosis of the graft 
and vein as well.  Sunitinib is a potent drug 
that is FDA approved and has more data 
backing it up than the ETS-1 inhibitor.  Thus, 
we believe we can get our product to market 
faster by using sunitinib.  We will still 
continue to study the ETS-1 inhibitor 
because it potentially has fewer side effects 




1) Set up of the release experiments 
 
 ReGel was stored in the freezer.  The gel was then thawed 
at room temperature, and while in liquid form, it was mixed 
with ETS-1 inhibitors at three different concentrations: 6.66, 
66.6, and 250 µg/mL.  Each ReGel+inhibitor sample was 
placed in a vial, where release medium was added.  The 
release medium was collected daily and then stored in the 
freezer until the day of analysis, and new medium was 
added.  
 
 2) ELISA experiments and analysis 
 
The basic methodology behind the drug release profile was 
to use a slightly modified indirect ELISA method (Figure 3) to 
obtain raw data.  This data was then put through a series of 
equations in Excel to obtain drug release graphs, such as 
the graph shown in Figure 8.   
 
In the conventional indirect ELISA method, the presence of 
an antibody is tested for by binding an antigen (blue) to the 
walls of a microtiter plate.  If the antibody is present, as 
shown in Example 1 in Figure 3, serum (pink) added to the 
sample as well as a color-marked enzyme-antibody 
conjugate (green) will bind in a chain, producing a color 
change and verifying the presence of the antibody [3].   
Our method (Figure 3) differed from conventional indirect 
ELISA in that we obtained plates that were already coated 
with streptavidin.  In addition, there was no competitive 
binding in our samples, and the only biotins introduced to the 
streptavadin surface were our molecules of interest (i.e., 
biotin-labeled ETS-1 peptide). 
  
ReGel® is a drug delivery system discovered at the 
University of Utah which has thermally sensitive properties.  
This delivery system is liquid at or below room temperature, 
but when it is exposed to body temperatures, it solidifies into 
a biodegradable polymer that is able to distribute drugs at a 
controlled rate.  One potential problem with ReGel is that it 
often has an initial period where a burst of drug is delivered 
[1].  However, one group of researchers was able to 
manipulate ReGel composition to achieve a continuous 35-
day release [2]. 
 
Because ReGel is able to solidify at the specific site where 
the drug is needed, it presents a unique opportunity for drug 
delivery in our case.  Figure 1 illustrates the main problem 
we are trying to address in our research, the narrowing 
(stenosis) that occurs in the region between the graft and the 
vein.  Figure 2 demonstrates the basic flow direction of the 
graft in a simplified scheme. 
 
The main goal of this portion of our experiment has been to 
obtain a drug release profile.  This profile is important 
because it shows whether the drug is releasing at a steady 
rate, and which concentration of drug will release most 
steadily at a therapeutic level.   
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Figure 3. Indirect ELISA method [5]. Figure 4. Cumulative Release of the 
ETS-1 Inhibitor. 
Figure 1. Stenosis at the venous anastomosis 
(the region between the graft and the vein) [3]. 
Figure 2. Diagram of the insertion of 
a graft and basic flow direction [4].   
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